#1 Clinical Trials Search in Europe

Metoclopramide Hydrochloride Anhydrous

This article discusses the use of Metoclopramide Hydrochloride Anhydrous in clinical trials for cancer treatment. Metoclopramide is a medication commonly used to treat nausea and vomiting, but researchers are exploring its potential benefits in cancer therapy. The trials mentioned here focus on colorectal cancer and breast cancer, investigating how Metoclopramide may be used alongside other treatments to improve patient outcomes.

Table of Contents

What is Metoclopramide Hydrochloride Anhydrous?

Metoclopramide Hydrochloride Anhydrous is an active substance used in various medications. It belongs to a class of drugs known as antiemetics and gastroprokinetics[1]. This means it helps prevent nausea and vomiting while also improving the movement of food through the digestive system.

What is Metoclopramide Used For?

Metoclopramide is primarily used to treat and prevent various gastrointestinal issues. Some of its main applications include:

  • Preventing nausea and vomiting, especially in patients undergoing chemotherapy or experiencing side effects from other medications[1]
  • Treating gastroesophageal reflux disease (GERD)
  • Improving symptoms of gastroparesis (delayed stomach emptying)
  • Managing nausea and vomiting associated with migraines

In clinical trials, metoclopramide is sometimes used as an auxiliary medication to manage potential side effects of other treatments[2].

How is Metoclopramide Administered?

Metoclopramide is available in various forms, including:

  • Tablets (e.g., Metoclopramide Accord 10 mg tablets, Metoclopramide “Orifarm” tablets)[1][2]
  • Oral solution
  • Injectable solution for intravenous or intramuscular use

The most common route of administration is oral, typically in tablet form[1][2].

Dosage Information

The dosage of metoclopramide can vary depending on the specific condition being treated and the individual patient. However, based on the clinical trial data, some general dosage information includes:

  • Maximum daily dose: 30 mg[1][2]
  • Typical tablet strength: 10 mg[1]
  • Treatment duration: Can vary, but in the clinical trials mentioned, it ranged from 30 days to 18 weeks[1][2]

It’s important to note that dosage should always be determined by a healthcare professional based on the individual patient’s needs and medical condition.

Potential Side Effects

Like all medications, metoclopramide can cause side effects. Some potential side effects may include:

  • Drowsiness or dizziness
  • Restlessness or agitation
  • Diarrhea
  • Headache
  • In rare cases, movement disorders or muscle stiffness

It’s important to report any unusual or severe side effects to your healthcare provider promptly.

Precautions and Considerations

When using metoclopramide, there are several important precautions to keep in mind:

  • Inform your doctor about any existing medical conditions, especially any history of movement disorders or gastrointestinal problems
  • Metoclopramide may interact with other medications, so inform your healthcare provider about all drugs you’re taking
  • Avoid alcohol while taking metoclopramide, as it can increase side effects
  • Use caution when driving or operating machinery, as metoclopramide can cause drowsiness

Ongoing Research

Metoclopramide continues to be studied in various clinical settings. In the clinical trials mentioned, it was used as an auxiliary medication in studies involving patients with colorectal cancer and breast cancer[1][2]. This highlights its potential role in managing side effects associated with cancer treatments, particularly chemotherapy-induced nausea and vomiting.

As research progresses, we may gain more insights into the optimal use of metoclopramide in different patient populations and treatment scenarios.

Aspect Details
Drug Name Metoclopramide Hydrochloride Anhydrous
Cancer Types Studied Colorectal cancer, HER2-positive breast cancer
Administration Oral tablets
Maximum Daily Dose 30 mg
Treatment Duration Up to 30 days in one trial, up to 18 weeks in another
Main Objectives Assess treatment effectiveness, evaluate progression-free survival, determine safety and tolerability, monitor quality of life
Key Endpoints Pathologic complete remission, progression-free survival, adverse events, quality of life measures
Eligibility Criteria Confirmed cancer diagnosis, specific performance status, adequate organ function
Exclusion Criteria Certain medical conditions, prior treatments, pregnancy or breastfeeding

FAQ

  • What is Metoclopramide Hydrochloride Anhydrous? Metoclopramide Hydrochloride Anhydrous is a medication primarily used to treat nausea and vomiting. In these clinical trials, it's being studied as a supportive treatment for cancer patients undergoing chemotherapy or other cancer treatments.
  • What types of cancer are being studied in these trials? The clinical trials mentioned in this article focus on colorectal cancer and HER2-positive breast cancer. These trials are exploring how Metoclopramide can be used alongside other cancer treatments to potentially improve patient outcomes.
  • How is Metoclopramide administered in these trials? In these trials, Metoclopramide is administered orally in tablet form. The maximum daily dose is 30 mg, and the treatment period can last up to 30 days in one trial and up to 18 weeks in another.
  • Are there any specific eligibility criteria for participating in these trials? Yes, each trial has specific eligibility criteria. For example, participants must have confirmed diagnoses of the specific cancer type being studied, meet certain performance status requirements, and have adequate organ function. There are also exclusion criteria, such as certain medical conditions or prior treatments that may disqualify a person from participating.
  • What are the main objectives of these clinical trials? The main objectives of these trials include assessing the effectiveness of treatment combinations that include Metoclopramide, evaluating progression-free survival, determining safety and tolerability of the treatments, and monitoring quality of life changes during the therapy course.

Ongoing Clinical Trials on Metoclopramide Hydrochloride Anhydrous

  • Study Comparing Trastuzumab Deruxtecan with Standard Treatment for Patients with HER2-positive Breast Cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Norway Sweden

  • Study of Oxaliplatin and Nivolumab for Patients with Metastatic Colorectal Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

Glossary

  • Metoclopramide Hydrochloride Anhydrous: A medication primarily used to treat nausea and vomiting, being studied in cancer treatment as a supportive therapy.
  • HER2-positive breast cancer: A type of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells.
  • Colorectal cancer: Cancer that starts in the colon or rectum, parts of the large intestine.
  • Neoadjuvant treatment: Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery.
  • Pathologic complete remission (pCR): The absence of all detectable cancer in tissue samples removed during surgery or biopsy after treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Adverse events: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Quality of life: The standard of health, comfort, and happiness experienced by an individual or group.
  • Biomarker: A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.

References

  1. http://clinicaltrials.eu/trial/study-of-oxaliplatin-and-nivolumab-for-patients-with-metastatic-colorectal-cancer/
  2. http://clinicaltrials.eu/trial/study-comparing-trastuzumab-deruxtecan-with-standard-treatment-for-patients-with-her2-positive-breast-cancer/